Literature DB >> 31465274

Melatonin As a Modulator of Degenerative and Regenerative Signaling Pathways in Injured Retinal Ganglion Cells.

Kobra B Juybari1, Azam Hosseinzadeh2, Habib Ghaznavi3, Mahboobeh Kamali4, Ahad Sedaghat5, Saeed Mehrzadi2, Masood Naseripour5.   

Abstract

Optic neuropathies refer to the dysfunction or degeneration of optic nerve fibers caused by any reasons including ischemia, inflammation, trauma, tumor, mitochondrial dysfunction, toxins, nutritional deficiency, inheritance, etc. Post-mitotic CNS neurons, including retinal ganglion cells (RGCs) intrinsically have a limited capacity for axon growth after either trauma or disease, leading to irreversible vision loss. In recent years, an increasing number of laboratory evidence has evaluated optic nerve injuries, focusing on molecular signaling pathways involved in RGC death. Trophic factor deprivation (TFD), inflammation, oxidative stress, mitochondrial dysfunction, glutamate-induced excitotoxicity, ischemia, hypoxia, etc. have been recognized as important molecular mechanisms leading to RGC apoptosis. Understanding these obstacles provides a better view to find out new strategies against retinal cell damage. Melatonin, as a wide-spectrum antioxidant and powerful freeradical scavenger, has the ability to protect RGCs or other cells against a variety of deleterious conditions such as oxidative/nitrosative stress, hypoxia/ischemia, inflammatory processes, and apoptosis. In this review, we primarily highlight the molecular regenerative and degenerative mechanisms involved in RGC survival/death and then summarize the possible protective effects of melatonin in the process of RGC death in some ocular diseases including optic neuropathies. Based on the information provided in this review, melatonin may act as a promising agent to reduce RGC death in various retinal pathologic conditions. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Retinal ganglion cell survival/death; apoptosis; excitotoxic damage; inflammation; melatonin; oxidative stress.

Mesh:

Substances:

Year:  2019        PMID: 31465274     DOI: 10.2174/1381612825666190829151314

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  11 in total

1.  Systematic Review of the Common Pathophysiological Mechanisms in COVID-19 and Neurodegeneration: The Role of Bioactive Compounds and Natural Antioxidants.

Authors:  Kyonghwan Choe; Hyun Young Park; Muhammad Ikram; Hyeon Jin Lee; Tae Ju Park; Rahat Ullah; Myeong Ok Kim
Journal:  Cells       Date:  2022-04-11       Impact factor: 7.666

Review 2.  Melatonin and urological cancers: a new therapeutic approach.

Authors:  Mohammad Hossein Mehrzadi; Azam Hosseinzadeh; Kobra Bahrampour Juybari; Saeed Mehrzadi
Journal:  Cancer Cell Int       Date:  2020-09-10       Impact factor: 5.722

3.  A Topical Formulation of Melatoninergic Compounds Exerts Strong Hypotensive and Neuroprotective Effects in a Rat Model of Hypertensive Glaucoma.

Authors:  Massimo Dal Monte; Maurizio Cammalleri; Rosario Amato; Salvatore Pezzino; Roberta Corsaro; Paola Bagnoli; Dario Rusciano
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

4.  Melatonin Inhibits Dengue Virus Infection via the Sirtuin 1-Mediated Interferon Pathway.

Authors:  Atthapan Morchang; Shilu Malakar; Kanchanaphan Poonudom; Sansanee Noisakran; Pa-Thai Yenchitsomanus; Thawornchai Limjindaporn
Journal:  Viruses       Date:  2021-04-11       Impact factor: 5.048

Review 5.  An updated review of mechanistic potentials of melatonin against cancer: pivotal roles in angiogenesis, apoptosis, autophagy, endoplasmic reticulum stress and oxidative stress.

Authors:  Saeed Mehrzadi; Mohammad Hossein Pourhanifeh; Alireza Mirzaei; Farid Moradian; Azam Hosseinzadeh
Journal:  Cancer Cell Int       Date:  2021-03-31       Impact factor: 5.722

Review 6.  Potential Effects of Melatonin and Micronutrients on Mitochondrial Dysfunction during a Cytokine Storm Typical of Oxidative/Inflammatory Diseases.

Authors:  Virna Margarita Martín Giménez; Natalia de Las Heras; León Ferder; Vicente Lahera; Russel J Reiter; Walter Manucha
Journal:  Diseases       Date:  2021-04-14

Review 7.  New Advances on Pathophysiology of Diabetes Neuropathy and Pain Management: Potential Role of Melatonin and DPP-4 Inhibitors.

Authors:  Prabhakar Busa; Yaswanth Kuthati; Niancih Huang; Chih-Shung Wong
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

Review 8.  Melatonin effect on platelets and coagulation: Implications for a prophylactic indication in COVID-19.

Authors:  Azam Hosseinzadeh; Abolfazl Bagherifard; Fereshteh Koosha; Shiva Amiri; Arman Karimi-Behnagh; Russel J Reiter; Saeed Mehrzadi
Journal:  Life Sci       Date:  2022-08-06       Impact factor: 6.780

Review 9.  Clinical Application of Melatonin in the Treatment of Cardiovascular Diseases: Current Evidence and New Insights into the Cardioprotective and Cardiotherapeutic Properties.

Authors:  Mohammad Hossein Pourhanifeh; Ehsan Dehdashtian; Azam Hosseinzadeh; Seyed Hashem Sezavar; Saeed Mehrzadi
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-14       Impact factor: 3.727

10.  Intravitreous delivery of melatonin affects the retinal neuron survival and visual signal transmission: in vivo and ex vivo study.

Authors:  Ye Tao; Bang Hu; Zhao Ma; Haijun Li; Enming Du; Gang Wang; Biao Xing; Jie Ma; Zongming Song
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.